8-K: Invivyd Receives EUA Termination Notice for PEMGARDA

Invivyd, Inc. announced it has received a twelve-month advanced notice of termination for the Emergency Use Authorization (EUA) of its COVID-19 monoclonal antibody, PEMGARDA, from the U.S. FDA, effective June 29, 2027.

Summary

• Invivyd, Inc. has received official notification from the U.S. Food and Drug Administration (FDA) regarding the termination of the Emergency Use Authorization (EUA) for its COVID-19 monoclonal antibody, PEMGARDA (pemivibart).
• This termination follows an earlier announcement by the U.S. Department of Health and Human Services (HHS) of the termination of the COVID-19 EUA declaration.
• The EUA for PEMGARDA will officially end on June 29, 2027, providing a twelve-month transition period.
• PEMGARDA has been authorized under EUA since March 2024 for pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised individuals who may not respond adequately to vaccination.
• Invivyd is currently in dialogue with the FDA to discuss appropriate next steps for PEMGARDA, aiming to secure permanent medical protection for vulnerable populations.
• The company believes PEMGARDA has sufficient clinical and post-authorization data to support a Biologics License Application (BLA) submission and approval.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative development. While the termination of an EUA is an expected outcome as the pandemic evolves, it presents a significant hurdle for PEMGARDA's continued availability and Invivyd's commercial strategy for this product.

Positives

• PEMGARDA has demonstrated strong protection from COVID-19 in a randomized clinical trial and has been in clinical use for over two years.
• The drug is considered a critical non-vaccine option for vulnerable Americans, combining high antiviral activity with an attractive safety profile.
• The twelve-month transition period allows for continued dialogue with the FDA and planning for future steps.
• Invivyd intends to pursue all avenues to secure permanent medical protection for immune-compromised and vulnerable Americans.

Negatives

• The Emergency Use Authorization (EUA) for PEMGARDA is set to terminate on June 29, 2027.
• The company has not yet received explicit written advice from HHS or FDA regarding a regulatory approval pathway for PEMGARDA.
• There are limitations to the data supporting PEMGARDA's benefits, including variability in EC50 values, pharmacokinetic data, and efficacy estimates from prior trials.
• Emergence of SARS-CoV-2 variants with substantially reduced susceptibility to PEMGARDA could impact its effectiveness.
• Anaphylaxis has been observed with PEMGARDA, and it carries a boxed warning for this risk.

Risks

• Uncertainties regarding the impact of the EUA termination on the company's business.
• Regulatory authorization or approval processes for PEMGARDA and available development pathways.
• Whether sufficient data is available to support a BLA submission and approval for PEMGARDA.
• Changes in the regulatory environment and the outcome of engagements with regulators.
• The timing, progress, and results of discovery, preclinical, and clinical development activities.
• Unexpected safety or efficacy data observed during studies or trials.
• The risk that results from nonclinical studies or clinical trials may not be predictive of future results.
• The ability to maintain an acceptable safety, tolerability, and efficacy profile post-authorization or approval.
• Uncertainties regarding market acceptance, payor coverage, and reimbursement.
• The success of the company's sales force and its ability to maintain and expand commercialization capabilities.
• Changes in expected or existing competition.
• Potential variability in neutralizing activity of product candidates against SARS-CoV-2 variants.
• The risk that a lack of awareness of mAb therapies and regulatory scrutiny may adversely impact development or commercial success.
• Reliance on third parties and complexities of manufacturing mAb therapies.
• Macroeconomic and political uncertainties.
• Whether the company has adequate funding to meet future operating expenses and capital expenditure requirements.

Future Outlook

Invivyd intends to pursue all avenues to secure permanent, high-quality medical protection from COVID infection for immune-compromised and other vulnerable Americans. The company is in dialogue with the FDA regarding next steps for PEMGARDA, believing it has sufficient data to support a Biologics License Application (BLA) submission and approval.

Management Comments

• "The end of a formal emergency for COVID products is in many ways overdue. While an EUA designation granted to PEMGARDA by the U.S. FDA in March 2024 has allowed thousands of vulnerable Americans access to a non-vaccine COVID-prevention option for over two years, the EUA designation is not a product approval."
• "At Invivyd, we believe PEMGARDA has sufficient clinical and post-authorization data to support Biologics License Application (BLA) submission and approval, and we regret that procedural uncertainty has needlessly intruded into our work on behalf of vulnerable Americans, who may find these headlines worrying and confusing."
• "Our view at Invivyd is unchanged over years: Invivyds monoclonal antibodies for COVID prevention have generated more randomized clinical data than comparable COVID-19 vaccine boosts, which have all received full approval via BLA, and we feel as though a full approval of PEMGARDA is well-warranted at this time by the totality of demonstrated safety and efficacy data both from the CANOPY pivotal trial and from growing clinical practice."
• "We are in dialogue with the FDA on appropriate next steps."

Industry Context

StockSavvy.ai notes that the termination of an Emergency Use Authorization (EUA) for a COVID-19 therapeutic, like PEMGARDA, reflects the evolving landscape of the pandemic from an emergency phase to a more endemic state. This transition often leads regulatory bodies to reassess the necessity of EUA status for products that have not yet achieved full Biologics License Application (BLA) approval. The company's stated intent to pursue BLA submission highlights the industry's ongoing efforts to transition promising treatments from emergency use to full market approval, even as the immediate public health emergency wanes.

Stakeholder Impact

• Shareholders may be concerned about the future commercial viability of PEMGARDA without EUA status and the potential impact on revenue.
• Immune-compromised and vulnerable Americans who rely on PEMGARDA for COVID-19 prevention may experience anxiety regarding future access to this treatment option.
• Healthcare providers will need to adapt to the termination of the EUA and understand the implications for prescribing and administering PEMGARDA during the transition period.

Next Steps

• Invivyd is in dialogue with the FDA about appropriate next steps for PEMGARDA.
• Invivyd intends to pursue every avenue to secure permanent, high-quality medical protection from COVID infection for immune-compromised and other vulnerable Americans.
• Invivyd believes PEMGARDA has sufficient clinical and post-authorization data to support Biologics License Application (BLA) submission and approval.

Key Dates

Recommendation

The filing indicates the termination of the EUA for PEMGARDA, which is a significant event for Invivyd. While the company plans to pursue BLA approval and has a twelve-month transition period, the uncertainty surrounding full approval and the potential loss of a key product's market access warrants a cautious 'hold' stance until further clarity on the regulatory pathway and commercial strategy emerges.

Keywords

PEMGARDA, pemivibart, EUA, FDA, COVID-19, monoclonal antibody, biopharmaceutical, immune compromise, pre-exposure prophylaxis, regulatory approval, BLA, Invivyd